mazdutide vs survodutide

mazdutide (A-tier) vs survodutide (A-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

mazdutide — tier A

the GLP-1 + glucagon dual agonist approved in China. ~14% weight loss in GLORY-1 phase 3 at 48 weeks, ~20% at the higher dose. not FDA-approved.

the glucagon/GLP-1 dual agonist that reached approval first, in China. real phase 3 efficacy, real label, but the pivotal data is single-ethnicity and there is no US approval.

NMPA '25 approved in China · half-life ~once-weekly dosing · weight loss

survodutide — tier A

boehringer and zealand's glucagon/GLP-1 dual agonist. 16.6% weight loss in the SYNCHRONIZE-1 phase 3, and a standout liver result. investigational, not approved.

a GLP-1 plus glucagon dual agonist with phase 3 obesity data and a breakthrough-tier liver story. still investigational, not FDA-approved.

16.6% SYNCHRONIZE-1 phase 3 · half-life ~6 days · weight loss

at a glance

• mazdutide: tier A · NMPA '25 approved in China
• survodutide: tier A · 16.6% SYNCHRONIZE-1 phase 3

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.